• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytometry, Part B. Clinical cytometry: the journal of the International Society for Analytical Cytology >Issue highlights - March 2013
【24h】

Issue highlights - March 2013

机译：发行要点-2013年3月

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multicolor flow cytometry was quite a technical novelty some years ago but today it became a daily diagnostic service in several flow cytometry laboratories. The publication of Sartor and Gottlieb in this issue of the journal (1) utilizes the advancement in flow technology and the wide array of reagent availability and they described a 10 color single tube flow cytometry assay to optimize the accuracy and sensitivity of minimal residual disease (MRD) detection. One particular problem in detecting MRD is the occurrence of cytopenia that may hamper the identification of residual cells when analyzing several tubes. Placing all of the informative markers in one tube reduces the total number of lymphocytes required for analysis in patients with lymphopenia following chemotherapy and facilitates direct exclusion of contaminating T cells during cell analysis. The assay was established and intended for use only by reference laboratories experienced in multi-parameter flow cytometry for CLL. This way of MRD detection, however also requires advanced instrumentation and thus cannot be achieved in several smaller laboratories. Literature from developing countries addressing therapeutic or laboratory practices related to MRD, is largely lacking, as in many resource-poor countries this advanced type of MRD detection is not feasible. Patkar and coworkers in their first paper from India published last year in this journal (2) described their experience in establishing a flow cytometry-based MRD assay for precursor B lineage ALL (BCP-ALL) with emphasis on assay standardization and cost. They utilized a 4-color approach that allowed MRD analysis at diagnosis and at two follow-up time points to be done in total for $100–150 and they found that this cost-effective MRD panel was applicable to over 90% of patients.
机译：多色流式细胞术在几年前是一个相当新颖的技术，但是今天它已成为多个流式细胞术实验室的日常诊断服务。 Sartor和Gottlieb在本期杂志（1）上的出版物利用了流技术的进步和广泛的试剂可用性，他们描述了一种10色单管流式细胞术测定法，以优化最小残留疾病的准确性和敏感性（ MRD）检测。检测MRD的一个特殊问题是发生血细胞减少症，这可能会妨碍分析多个试管时残留细胞的鉴定。将所有信息标记物置于一根试管中可减少化疗后淋巴细胞减少症患者分析所需的淋巴细胞总数，并有助于在细胞分析过程中直接排除污染的T细胞。该测定法已建立，仅供在CLL多参数流式细胞术中有经验的参考实验室使用。但是，这种MRD检测方法还需要先进的仪器，因此无法在几个较小的实验室中实现。基本上缺乏来自发展中国家的有关MRD的治疗或实验室方法的文献，因为在许多资源匮乏的国家，这种先进的MRD检测方法是不可行的。 Patkar和他的同事去年在该期刊上发表的来自印度的第一篇论文（2）中介绍了他们建立基于流式细胞仪的MRD检测前体B谱系ALL（BCP-ALL）的经验，并着重于分析的标准化和成本。他们采用了4色方法，可以在诊断时和在两个随访时间点进行MRD分析，总计花费100-150美元，他们发现这种具有成本效益的MRD面板适用于90％以上的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号